Advanced search
Treatment with gemcitabine and oxaliplatin plus bevacizumab in patients with advanced biliary-tract cancers demonstrated antitumor activity and had a tolerable safety profile.
In this phase-2 trial, researchers randomly assigned 35 patients to bevacizumab (Avastin, Genentech) ...
FULL STORY
November 27 - 29, 2009
Barcelona
more information »
November 29, 2009 - December 04, 2009
Chicago, IL
December 05 - 08, 2009
New Orleans, LA
"Cervical cancer has less mortality, and the amount of money that gets spent on that is amazing…"
Read full post here »
International Conference on Molecular Targets and Cancer Therapeutics